Caplin Steriles signs license & supply agreement with baxter healthcare corporation.

– Caplin Steriles will out-license five of its injectable AND As to Baxter Healthcare Corporation .

Chennai, April 08,2019: Caplin Point Laboratories Limited (BSE: CAPLL (524742), NSE:CAPLIPOINT) announced that Caplin Steriles Limited (a Wholly Owned Subsidiary of Caplin Point Laboratories Ltd) has entered into a license and supply agreement with Baxter Healthcare Corporation for five generic injectable ANDAs.

Commenting on the transaction, Mr C.C.Paarthipan, Chairman, Caplin Point Laboratories Limited, said: “We’re glad to enhance our partnership with Baxter with this agreement. All these ANDAs have been developed in-house, and we’re keen to license them to Baxter, who have an excellent sales and marketing infrastructure in the US for commercialization of these products.” Specific terms of the agreement were not disclosed.


Caplin Steriles Ltd, a Wholly Owned Subsidiary Company of Caplin Point Laboratories Limited, is a niche sterile product manufacturing company that is approved by US FDA and EU-GMP. The company has filed 11 ANDAs so far, with 4 approvals. The company has a larger pipeline of 40+ ANDAs that it intends to file over the next 5 years.


Caplin Point Laboratories Limited is a fast growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point Laboratories Limited has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company has also entered regulated markets such as US through its Wholly Owned Subsidiary Caplin Steriles

Caplin Point has been selected on Forbes Asia’s “200 Best Under a Billion” list for three consecutive years (2014, 2015 & 2016), and was recently awarded “The Emerging Company of 2018” by Economic Times Family Business Awards.